Join us on January 29, 2020 at 11:00 AM EST for a webinar on Hepatitis Delta Treatment Endpoints: How Do We Measure Success in the Era of Emerging Therapies?
Hepatitis delta, a dangerous coinfection of hepatitis B, is estimated to affect between 15 and 70 million people across the world. For decades, the only treatment option has been pegylated interferon; an often difficult drug to tolerate with only a small chance of controlling liver disease. With many new drugs now in clinical trials for hepatitis delta, we must ask, what does successful treatment look like?
- How can we measure success?
- What does it mean to control hepatitis delta?
- Is a cure for hepatitis B the only ideal endpoint of treatment?
Join hepatitis delta expert, Dr. Ohad Etzion, as he outlines the challenges in controlling the disease, current clinical trials, and explores ideal endpoints for treatment and control of hepatitis B and delta coinfection.
Please join NASTAD’s Hepatitis Testing Partnership and Hep B United on November 12, 2019 at 2:00 PM EST for a webinar to discuss efforts to increase hepatitis B testing and vaccination in correctional facilities.
In the U.S., rates of acute hepatitis B infection among adults are on the rise in many states as a consequence of the opioid crisis. Individuals at risk for hepatitis B infection and recommended for hepatitis B testing include injection-drug users, persons infected with HIV, and persons born in geographic regions with a hepatitis B prevalence of >2%, among others.
Incarcerated persons often have a disproportionate burden of infectious diseases, including hepatitis B infection. The Advisory Committee on Immunization Practices (ACIP) recommends universal hepatitis B vaccination of adults in high-risk settings including correctional facilities. In this webinar, panelists will share efforts to increase hepatitis B testing and vaccination in state jails and prisons in Maine, Oregon, and Tennessee.
Jeff Caulfield, MPH, Viral Hepatitis Prevention Coordinator, Maine Center for Disease Control and Prevention
Rebecca Lakey, RNI Viral Hepatitis Prevention Program, East Tennessee Regional Health Office, Tennessee Department of Health
Judith Leahy, MPH, Viral Hepatitis Coordinator, Public Health Division, Oregon Health Authority
Ann A. Chakwin, PhD, Health Promotion Program Coordinator, Oregon Department of Corrections
Please join the Global Liver Institute, American Gastroenterological Association, Hepatitis B Foundation, Hep B United, NASH kNOWledge, AAPCHO, NVHR, and NASTAD as they host a Congressional briefing titled, “Liver Cancer Drivers and Disparities.” The briefing will be held on Thursday, October 31st, from 10:30am to 12:00pm in Washington, DC (121 Cannon House Office Building).
Learn from our nation’s leading clinicians and patient advocates about the steps needed to combat the most rapidly rising cancer since 1980, and how response strategies must begin with modernizing the systems in place to better meet the needs of impacted populations.
Join the conversation on Facebook Live at www.facebook.com/hepbfoundation on October 31, 2019 at 10:30 am Eastern Time.
Congresswoman Nydia Velázquez (NY)
Donna Cryer, JD, President & CEO, Global Liver Institute (GLI), Washington, DC
- Tony Villiotti, President, NASH kNOWledge, GLI A3 Patient Advocate, Pittsburgh, PA
- Dr. Richard Sterling, MD, MSc, FACP, FACG, AGAF, FAASLD, VCU Hepatology Professor of Medicine, Chief, Section of Hepatology, Director, Viral Hepatitis, Medical Director, Department of Internal Medicine, VCU Medical School, AGA, Richmond, VA
- Valerie Green, NVHR Patient Advocate, Lancaster, VA
- Dr. John Groopman, PhD, Anna M. Baetjer Professor & Associate Director for Population Sciences, Joint Appointment in Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
October is Liver Cancer Awareness Month! Did you know that in the U.S., the rates of liver cancer incidence and deaths are increasing while most other cancer rates have declined or stabilized? Please join Hep B United on October 21, 2019 at 1:00 PM EDT for a webinar to discuss the link between hepatitis B and liver cancer.
In the U.S., up to 2.2 million people are living with chronic hepatitis B infection, only 25 percent are aware of their infection, and less than 10 percent of infected individuals are able to access care and receive treatment. Left untreated, hepatitis B can lead to premature death from liver cancer or liver failure. Panelists will discuss liver cancer and its risk factors, the Centers for Disease Control and Prevention (CDC) National Comprehensive Cancer Control Program, and promising state-based initiatives and strategies for liver cancer prevention, including hepatitis B vaccination awareness and provider education activities.
Behnoosh Momin, DrPH, MS, MPH, Health Scientist, CDC Division of Cancer Prevention and Control
Charlene Cariou, MHS, CPH, CHES, Health Program Manager, Comprehensive Cancer Control, Division of Public Health, Idaho Department of Health and Welfare
Jacki Chen, #justB Storyteller and Patient Advocate
Hep B United National Coalition Convenes in Washington DC for 7th Annual Summit
WASHINGTON, D.C. (July 2019) –Hep B United, a national coalition established by the Hepatitis B Foundation (HBF) and the Association of Asian Pacific Community Health Organizations (AAPCHO) to address the silent epidemic of hepatitis B, will host its seventh annual summit in Washington, D.C., July 23rd to 25th. The summit brings together over 100 community leaders, advocates, and people with hepatitis B to promote screening and prevention strategies and advocate for equitable access to health care to further its mission to eliminate hepatitis B in the United States. Worldwide, nearly two-thirds of those infected with hepatitis B- over 200 million people- are unaware of that they are infected. Summit attendees will address ways to identify those “missing millions” who do not yet know that they are living with this often-silent disease.
Hepatitis B is caused by a virus and is the world’s most common, serious liver infection. It is also the deadliest vaccine-preventable disease, with nearly 1 million people dying each year from hepatitis B-related disease worldwide. In the United States, up to 2.2 million Americans are chronically infected with hepatitis B, yet most do not know it. Without early diagnosis and intervention, one in four people living with hepatitis B will die prematurely from liver failure or liver cancer.
“We can save millions of lives in the U.S. and worldwide by using the tools we have and building much-needed infrastructure to prevent, diagnose and treat hepatitis B,” said Chari Cohen, DrPH, MPH, senior vice president of the Hepatitis B Foundation and co-chair of Hep B United. “The annual Hep B United Summit brings our partners together to share best practices and develop strategies for the coming year to increase national attention and resources to address the epidemic of hepatitis B.”
The Hep B United summit is the largest convening of hepatitis B leaders from community coalitions, national nonprofit organizations, individuals and family members affected by hepatitis B, and public health agencies in the United States. Hep B United is comprised of more than 40 community coalitions across the country located in 29 cities, 20 states, and Washington, D.C. The summit is part of global events to mark World Hepatitis Day, observed each year on July 28th, the birthday of Dr. Baruch Blumberg, Nobel Laureate who discovered the hepatitis B virus and developed the first vaccine. The summit’s theme, “Eliminating Hepatitis B: Local Change, Global Impact,” includes sessions that share innovative local, national, and global programs to prevent, diagnose and treat hepatitis B. The summit will also feature #justB, Hepatitis B Foundation’s national storytelling campaign that tells the personal stories of people affected by hepatitis B to increase public awareness and combat stigma and discrimination.
Continue reading Hepatitis B Leaders Mark World Hepatitis Day with Pledge to Find the Missing Millions →
May is Hepatitis Awareness Month and May 19th marks the 8th annual Hepatitis Testing Day in the U.S.! Organizations around the U.S. are out and about spreading awareness about hepatitis B and hosting many hepatitis education and testing events. We are excited to share resources of opportunities for everyone to get involved in their community this month and throughout the year.
Check out our activity guide to find a local organization and event near you, CDC’s new Hepatitis Awareness Month and Testing Day homepage, and a short CDC video presentation that highlights the resources available for Hepatitis Awareness Month.
Finally, join Join Hepatitis B Foundation, NASTAD and CDC’s Division of Viral Hepatitis for a Twitter HepChat at 2 p.m. (ET) Thursday, June 13th. The chat will highlight Hepatitis Awareness Month outreach events and allow partner organizations to share their successes, challenges and lessons learned from their efforts. Keep us posted with your events throughout the month with the hashtag #Hepaware19 and remember to join the Twitter Chat conversation with the hashtag #HepChat19.
Join Hep B United on February 21st, 2019 from 3:00 pm to 4:00 pm EST for a webinar on dispelling common myths about hepatitis B!
How is hepatitis B spread?
If I am infected, can I safely breastfeed my baby?
What is the hepatitis B vaccine schedule?
We will tackle some of these questions, myths about hepatitis B transmission, and how to address common misconceptions. Join a conversation with our panelists and share your own questions about hepatitis B transmission and prevention.
Maureen Kamischke, Social Media and Outreach Manager, Hepatitis B Foundation
Ponni Perumalswami, MD, Associate Professor of Medicine and Hepatologist, Mount Sinai School of Medicine
Amy Shen Tang, MD, Hepatitis B Program Director and Primary Care Internist, Charles B. Wang Community Health Center
Please join Hep B United on Wednesday, January 23, 2019 at 3:00 pm EST for a webinar to learn about tools and resources to support the global elimination of hepatitis B. Globally, an estimated 292 million are living with chronic hepatitis B infection, yet only 10% are diagnosed. Additionally, out of the estimated 94 million eligible for treatment, of these, only 4.8 million or 5% were treated. Join us for this interactive session to learn about novel initiatives to expand epidemiological data through the Polaris Observatory and resources to increase access to hepatitis screening and treatment.
Join us for a Webinar: Hepatitis Delta: Current and Future Treatments
Tuesday, January 8th 2019
7:00 AM PT / 10:00 AM ET
While scientific advancements in the last 20 years have brought highly effective treatment options for hepatitis B patients; treatments for hepatitis B and delta coinfected patients have lagged behind. Interferon therapy remains the only somewhat effective treatment option for 15-20 million patients who are anxiously awaiting new drugs to control their coinfection. With 7 new drugs in clinical trials, there is hope.
Join professor Cihan Yurdaydin, MD, secretary general for the World Gastroenterology Organization and Educational Councilor of EASL, for an in-depth perspective on current treatment regimens for hepatitis delta and a look at new drugs in the pipeline that show promise for more effective future treatments.
Register here – even if you cannot attend live, please register and we will email you the webinar recording!